Press Release Biocartis Group NV: Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders
28 August 2023 - 7:00AM
Press Release Biocartis Group NV: Biocartis appoints new Medical
Advisory Board (MAB) of renowned practice leaders
PRESS RELEASE: 28 August 2023, 7:00 AM CEST
Biocartis
appoints new Medical Advisory Board
(MAB) of renowned practice
leaders
Mechelen, Belgium,
28 August
2023 - Biocartis Group NV (the
‘Company’ or ‘Biocartis’), an innovative molecular diagnostics
company (Euronext Brussels: BCART), is pleased to announce the
appointment of a global Medical Advisory Board (MAB) comprised on
renowned and influential KOLs in diagnostics, pharma and hospitals
to advise, inform and guide Biocartis’ expedited global growth in
the area of diagnostic partnerships and to provide valuable expert
technology insights (e.g. complementarity of Idylla™ with NGS or
other technologies), expert knowledge on the clinical diagnostic
needs in the field of oncology (e.g. regulatory insights, advocacy
groups) and expert guidance on defining future strategies for
pharma needs (e.g. reimbursement, cost and validation strategies).
The new MAB will become effective as of 28 August 2023, with
additional members joining within the coming weeks.
The Company is excited to welcome Anthony “Nino”
Sireci, MD, M.Sc. and Maria Arcila, MD to the Biocartis Medical
Advisory Board.
Anthony “Nino”
Sireci, MD,
M.Sc. is the Senior Vice President, Diagnostics
Development at Loxo Oncology at Lilly. Dr. Sireci is a board
certified Clinical Pathologist and a practicing molecular
pathologist. Prior to joining Loxo, he was an Assistant Professor
of Pathology and Cell Biology at Columbia University and a medical
director in the Laboratory of Personalized Genomic Medicine at
Columbia Medical Center. He is an active member of the Association
for Molecular Pathology (AMP) where he serves on the organizations’
Strategy Committee and was the former vice chair for new codes and
pricing on the Economic Affairs Committee. He is also a member of
the Pathology Coding Caucus in the College of American Pathologists
(CAP) and the Molecular Pathology Advisory Group in the American
Medical Association (AMA). Dr. Sireci received a B.A. in chemistry
from New York University, an MD from the Johns Hopkins University
School of Medicine and a Masters in Biostatistics from the Mailman
School of Public Health at Columbia University. He completed his
residency training in Clinical Pathology in the New
York-Presbyterian Hospital/Columbia, where he also served as chief
resident.
Maria
Arcila, MD received her MD degree
from the University of Pittsburgh School of Medicine and completed
postgraduate training in Anatomic and Clinical Pathology at Madigan
Army Medical Center, followed by subspecialty fellowships at
Memorial Sloan Kettering Cancer Center (MSKCC) in Molecular Genetic
Pathology and Hematopathology. She has served as Director of the
Molecular Pathology Laboratory at MSKCC and is currently the Deputy
Chief of the Molecular Diagnostic Service at the same institution.
Dr. Arcila’s research work highlights therapeutic and prognostic
molecular markers in solid tumors and hematologic malignancies and
her work focuses on the expansion, validation, and
implementation of clinical tests to optimize precision
medicine.
Commenting on the
newly appointed Medical
Advisory Board,
Biocartis' CEO, Roger
Moody, added: “Biocartis
is committed to improving patient care through faster diagnostics
and broader patient access. The Biocartis Medical Advisory Board
(MAB) is one of our top priorities as we commercialize tests
addressing these medical needs. These global leaders are in the
forefront of addressing oncology diagnostics, treatment and medical
intervention. We look forward to working with the Biocartis MAB as
the voice of immediate oncology needs to improve medical care and
expedited intervention.”
----- END ----
More informationInvestor Relations
Biocartise-mail ir@biocartis.com
About Biocartis
With its revolutionary and proprietary Idylla™
Platform, Biocartis (Euronext Brussels: BCART) aspires to enable
personalized medicine for patients around the world through
universal access to molecular testing, by making molecular testing
actionable, convenient, fast and suitable for any lab. The Idylla™
Platform is a fully automated sample-to-result, real-time PCR
(Polymerase Chain Reaction) based system designed to offer in-house
access to accurate molecular information in a minimum amount of
time for faster, informed treatment decisions. Idylla™'s
continuously expanding menu of molecular diagnostic tests address
key unmet clinical needs, with a focus in oncology. This is the
fastest growing segment of the molecular diagnostics market
worldwide. Today, Biocartis offers tests supporting melanoma,
colorectal, lung and liver cancer, as well as for sepsis. More
information: www.biocartis.com. Follow us on Twitter:
@Biocartis_.
Biocartis and Idylla™ are registered trademarks
in Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
Please refer to the product labeling for applicable intended uses
for each individual Biocartis product.
This press release is not for distribution,
directly or indirectly, in any jurisdiction where to do so would be
unlawful. Any persons reading this press release should inform
themselves of and observe any such restrictions. Biocartis takes no
responsibility for any violation of any such restrictions by any
person. This press release does not constitute an offer or
invitation for the sale or purchase of securities in any
jurisdiction. No securities of Biocartis may be offered or sold in
the United States of America absent registration with the United
States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended.
Forward-looking statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Okt 2023 bis Okt 2024